Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05566639 · ClinicalTrials.gov registry record · Phase 3
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
A Phase 3 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 3
- Development phase
- 22,502
- Enrollment target
NCT05566639 is a Phase 3 study that has completed, run by ModernaTX. The registered enrollment target is 22,502 participants.
The verdict
NCT05566639, a Phase 3 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 22,502 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
Interventions
- BIOLOGICAL mRNA-1010
- BIOLOGICAL Fluarix Quadrivalent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,502 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2024-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05566639
The ClinicalTrials.gov registry entry for NCT05566639 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 22,502 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which mRNA-1010 is the first listed.
NCT05566639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05566639 about?
NCT05566639 is a clinical study titled "A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older". The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
What is the current status of trial NCT05566639?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 22,502 participants. The study started on 2022-09-14. Estimated completion is 2024-01-05.
What interventions are being tested in trial NCT05566639?
The interventions under investigation include: mRNA-1010 (BIOLOGICAL), Fluarix Quadrivalent (BIOLOGICAL).
Who is sponsoring clinical trial NCT05566639?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.